Stock Price
3.61
Daily Change
-2.17%
Yearly
-21.52%

Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Peers Price Day Year
AbbVie 121.87 0.36 0.30% 12.15%
Adamas Pharmaceuticals 8.22 0.06 0.74% 91.16%
Aerie Pharmaceuticals 9.65 -0.11 -1.13% -19.92%
Alnylam Pharmaceuticals 176.92 -3.36 -1.86% 42.63%
Amarin 3.61 -0.08 -2.17% -21.52%
Arena Pharmaceuticals 54.71 2.05 3.89% -20.57%
AstraZeneca 8,354.00 70.00 0.85% 3.10%
BioCryst Pharmaceuticals 12.24 0.03 0.25% 68.60%
DBV Technologies 2.85 -0.03 -1.04% -0.70%
Epizyme 3.12 0 0% -74.21%
Esperion Therapeutics 5.87 0.31 5.58% -79.99%
GlaxoSmithKline 1,597.80 6.00 0.38% 12.73%
Halozyme Therapeutics 33.24 0.89 2.75% -15.87%
Heron Therapeutics 8.35 -0.67 -7.43% -52.20%
Intercept Pharmaceuticals 17.11 0.16 0.94% -48.62%
Ionis Pharmaceuticals 32.21 1.64 5.36% -34.24%
Jazz Pharmaceuticals 126.11 2.32 1.87% -13.65%
Neurocrine Biosciences 84.26 2.01 2.44% -8.38%
Nektar Therapeutics 12.73 0.55 4.52% -23.27%
Novartis 75.02 0.20 0.27% -7.72%
Teva Pharmaceutical Industries 8.46 0.04 0.48% -20.56%
Acceleron Pharma 178.75 -0.93 -0.52% 57.43%

Indexes Price Day Year
NASDAQ 15787 100.07 0.64% 27.94%

Amarin
Amarin Corporation plc is a biopharmaceutical company with operations in lipid science focused on the commercialization and development of therapeutics for cardiovascular health. The Company operates through the development and commercialization of Vascepa segment. The Company's lead product, Vascepa (icosapent ethyl) capsule, is approved by the United States Food and Drug Administration (FDA) for use as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia. This indication for Vascepa, known as the MARINE indication, is based primarily on the results from the MARINE study of Vascepa in this approved patient population. The Company sells Vascepa principally to wholesalers, as well as selected regional wholesalers and specialty pharmacy providers, or collectively, its distributors, which in turn resell Vascepa to retail pharmacies for resale to patients and healthcare providers.